CohBar (CWBR) 10-Q 11 Aug 15 2015 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 10, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Entity Registrant Name	CohBar, Inc.
Entity Central Index Key	1,522,602
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	COB.U
Entity Common Stock, Shares Outstanding		32,320,891

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 7,393,314	$ 1,194,492
Restricted cash	0	4,055
Investments	4,745,714	0
Prepaid expenses and other current assets	106,151	19,517
Total current assets	12,245,179	1,218,064
Property and equipment, net	209,435	4,631
Deferred offering costs	0	749,386
Other assets	17,712	1,100
Total assets	12,472,326	1,973,181
Current liabilities:
Accounts payable	224,687	290,073
Accrued liabilities	101,295	305,401
Accrued payroll and other compensation	80,588	103,294
Total current liabilities	406,570	698,768
Note payable, net of debt discount of $353 and $451 as of June 30, 2015 and December 31, 2014, respectively	204,907	204,809
Total liabilities	$ 611,477	$ 903,577
Commitments and contingencies
Stockholders’equity:
Common stock, $0.001 par value, Authorized 75,000,000 shares; Issued and outstanding 32,320,891 shares as of June 30, 2015 and 12,915,343 as of December 31, 2014	$ 32,321	$ 12,915
Additional paid-in capital	17,933,650	5,507,616
Accumulated deficit	(6,105,122)	(4,456,327)
Total stockholders’ equity	11,860,849	1,069,604
Total liabilities and stockholders’ equity	12,472,326	1,973,181
Series A Preferred Stock [Member]
Stockholders’equity:
Preferred Stock	0	0
Convertible Preferred Stock Series B [Member]
Stockholders’equity:
Preferred Stock	$ 0	$ 5,400

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Debt Instrument, Unamortized Discount	$ 353	$ 451
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	75,000,000	75,000,000
Common Stock, Shares, Issued	32,320,891	12,915,343
Common Stock, Shares, Outstanding	32,320,891	12,915,343
Series A Preferred Stock [Member]
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Convertible Preferred Stock Series B [Member]
Preferred Stock, Shares Issued	0	5,400,000
Preferred Stock, Shares Outstanding	0	5,400,000

Condensed Statements of Operati

Condensed Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues	$ 0	$ 0	$ 0	$ 0
Operating expenses:
Research and development	447,287	137,059	710,047	245,332
General and administrative	418,932	523,869	935,918	668,217
Total operating expenses	866,219	660,928	1,645,965	913,549
Operating loss	(866,219)	(660,928)	(1,645,965)	(913,549)
Other income (expense):
Interest income	1,022	216	2,199	247
Interest expense	(1,756)	(1,700)	(3,512)	(3,441)
Other expense	(528)	0	(1,419)	0
Amortization of debt discount	(49)	(155)	(98)	(235)
Total other income (expense)	(1,311)	(1,639)	(2,830)	(3,429)
Net loss	$ (867,530)	$ (662,567)	$ (1,648,795)	$ (916,978)
Basic and diluted net loss per share	$ (0.03)	$ (0.05)	$ (0.05)	$ (0.07)
Weighted average common shares outstanding - basic and diluted	32,320,891	12,915,343	31,763,073	12,915,343

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities:
Net loss	$ (1,648,795)	$ (916,978)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	7,875	1,249
Stock-based compensation	216,205	222,498
Amortization of debt discount	98	235
Changes in operating assets and liabilities:
Restricted cash	4,055	85,640
Prepaid expenses and other current assets	(86,634)	(20,279)
Accounts payable	(65,386)	102,428
Accrued liabilities	(204,106)	11,568
Accrued payroll and other compensation	(22,706)	6,927
Net cash used in operating activities	(1,799,394)	(506,712)
Cash flows from investing activities:
Purchases of property and equipment	(212,679)	0
Payment for security deposit	(16,612)	0
Purchases of investments	(6,243,714)	0
Proceeds from redemptions of investments	1,498,000	0
Net cash used in investing activities	(4,975,005)	0
Cash flows from financing activities:
Deferred offering costs	(35,811)	(28,355)
Proceeds from the issuance of preferred stock, net	0	2,330,079
Proceeds from convertible notes	0	210,000
Proceeds from initial public offering	10,253,484	0
Proceeds from exercise of stock options	55,548	0
Proceeds from conversion of private placement Puts	2,700,000	0
Net cash provided by financing activities	12,973,221	2,511,724
Net increase in cash and cash equivalents	6,198,822	2,005,012
Cash and cash equivalents at beginning of period	1,194,492	145,170
Cash and cash equivalents at end of period	7,393,314	2,150,182
Non-cash investing and financing activities:
Warrants issued in connection with bridge loans	0	138
Conversion of convertible notes to Series B Preferred Stock	0	210,000
Reclassification of deferred offering costs to equity	785,197	0
Conversion of Series B Preferred Stock to Common Stock	$ 5,400,000	$ 0

Business Organization and Basis

Business Organization and Basis of Presentation	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1 - Business Organization and Basis of Presentation CohBar, Inc. (“CohBar” or the “Company”) is a leader in the research and development of mitochondria-based therapeutics (“MBTs”), an emerging class of drugs for the treatment of diseases associated with aging. MBTs originate from the discovery by the Company’s founders of a novel group of peptides within the genome of mitochondria, the powerhouses of the cell. The Company’s ongoing development of mitochondrial-derived peptides (“MDPs”) into MBTs offers the potential to address a broad range of diseases such as type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders. The Company’s primary activities include conducting MDP research and development of its MBT pipeline, securing intellectual property protection, establishing relationships with Contract Research Organizations ( “ ” The unaudited interim condensed financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC”). They do not include all information and footnotes required by GAAP for complete financial statements. Except as disclosed herein, there have been no material changes in the information disclosed in the notes to the financial statements for the year ended December 31, 2014, included in the Company’s Annual Report on Form 10-K, filed with the SEC (the “2014 Form 10-K”). The interim unaudited condensed financial statements should be read in conjunction with those audited financial statements included in the 2014 Form 10-K. In the opinion of management, all adjustments considered necessary for fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three and six month periods ended June 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015, or any other period. All amounts are presented in U.S. Dollars.

Management's Liquidity Plans

Management's Liquidity Plans	6 Months Ended
	Jun. 30, 2015
Management's Liquidity Plans [Abstract]
Management's Liquidity Plans [Text Block]	Note 2 - Management’s Liquidity Plans As of June 30, 2015, the Company had working capital and stockholders’ equity of $ 11,838,609 11,860,849 1,648,795 In January 2015, the Company completed its Initial Public Offering (“IPO”) on the TSX Venture Exchange. The Company sold 11,250,000 1.00 11,250,000 2,700,000 2,700,000 13,950,000 With the cash on hand as of June 30, 2015, the Company believes that it has sufficient cash to meet its working capital needs and operating expenses into the early part of 2017. However, if unanticipated difficulties arise the Company may be required to raise additional capital to support its operations or curtail its research and development activities until such time as additional capital becomes available. There is no assurance that additional financing will be available when needed or that management will be able to obtain such financing on terms acceptable to the Company and that the Company will become profitable and generate positive operating cash flow in the future.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 3 - Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at dates of the financial statements and the reported amounts of revenue and expenses during the periods. Actual results could differ from these estimates. The Company’s significant estimates and assumptions include the fair value of the Company’s stock, stock-based compensation, debt discount and the valuation allowance relating to the Company’s deferred tax assets. The Company maintains deposits in a financial institution which is insured by the Federal Deposit Insurance Corporation (“FDIC”). At various times, the Company has deposits in this financial institution in excess of the amount insured by the FDIC. Investments Investments consist of U.S Treasury Bills and Certificates of Deposit. The Company determines the appropriate balance sheet classification of its investments at the time of purchase and evaluates the classification at each balance sheet date. The Company had $ 4,745,714 Deferred Offering Costs The Company classifies amounts related to the IPO not closed as of the balance sheet date as Deferred Offering Costs. During the six months ended June 30, 2015, the Company reclassified Deferred Offering Costs in the amount of $ 749,386 During the six months ended June 30, 2015, the Company incurred $ 35,811 The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company utilizes three levels of inputs that may be used to measure fair value: Level 1 - quoted prices in active markets for identical assets or liabilities Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions) The carrying amounts of cash, investments, accounts payable, accrued liabilities and debt approximate fair value due to the short-term nature of these instruments. The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provides the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company's own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control), or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its common stock purchase warrants and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required. The Company’s free standing derivatives consist of warrants to purchase common stock that were issued in connection with its notes payable, warrants to purchase common stock that were issued in connection with the Company’s IPO and concurrent private placement and compensation options issued to the agents in the IPO exercisable for shares of common stock and common stock purchase warrants. The Company evaluated these securities to assess their proper classification using the applicable criteria enumerated under U.S. GAAP and determined that they meet the criteria for equity classification in the condensed balance sheet as of June 30, 2015 and December 31, 2014. The Company accounts for share-based payments using the fair value method. For employees and directors, the fair value of the award is measured, as discussed below, on the grant date. For non-employees, fair value is generally valued based on the fair value of the services provided or the fair value of the equity instruments on the measurement date, whichever is more readily determinable and re-measured on each financial reporting dates until the service is complete. The Company has granted stock options at exercise prices no less than the fair market value as determined by the board of directors, with input from management. The weighted-average fair value of options and warrants has been estimated on the date of grant using the Black-Scholes pricing model. The fair value of each instrument is estimated on the date of grant utilizing certain assumptions for a risk free interest rate, volatility and expected remaining lives of the awards. Since the Company has a limited history of being publicly traded, the fair value of stock-based payment awards issued was estimated using a volatility derived from an index of comparable entities. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company’s stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company’s forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the number of vested options as a percentage of total options outstanding. If the Company’s actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period. For The Three And Six Months Ended June 30, 2015 2014 Expected life 4 years 6 years Risk free interest rate 1.32% 2.67% Expected volatility 80% 80% Expected dividend yield 0% 0% As of June 30, 2015, total unrecognized stock option compensation expense is $ 771,236 Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. June 30, June 30,* 2015 2014 Options 3,340,959 1,225,219 Warrants 7,936,391 833,617 Preferred Stock Series B - 2,600,000 Totals 11,277,350 4,658,836 * June 30, 2014 does not include shares and common stock purchase warants issuable under Put Agreements contingent upon the completion of the IPO. Recent accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s financial statements upon adoption.

Accrued Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 4 - Accrued Expenses As of As of June 30, 2015 December 31, 2014 Lab services $ 44,329 $ 64,768 Professional fees 36,820 173,829 Consultant fees 4,000 52,000 Interest 14,315 10,804 Expense reimbursement 1,831 4,000 Total accrued expenses $ 101,295 $ 305,401

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 5 - Commitments and Contingencies Litigations, Claims and Assessments The Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. There are no such matters that are included in the condensed financial statements as of June 30, 2015. Operating Lease In February 2015, the Company entered into a lease agreement for a new and expanded laboratory. The laboratory space is leased on a month-to-month basis and is part of a shared facility in Menlo Park, California. Rent expense was $ 26,727 5,400 45,742 10,800

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 6 - Stockholders’ Equity Authorized Capital In January 2015, the Company completed its IPO on the TSX Venture Exchange. The Company sold 11,250,000 1.00 11,250,000 2,700,000 2,700,000 13,950,000 12,953,484 13,950,000 6,975,000 Each whole warrant is exercisable to acquire one share of CohBar's common stock at a price of $2.00 per share at any time up to January 6, 2017, subject to CohBar's right to accelerate the expiration time of the warrants if at any time the volume-weighted average trading price of its common stock is equal to or exceeds $3.00 per share for twenty (20) consecutive trading days. 786,696 1.00 In January 2015, the Company amended its Certificate of Incorporation to increase the total number of authorized shares of common stock. Following the amendment, the Company has authorized the issuance and sale of up to 80,000,000 75,000,000 0.001 5,000,000 0.001 In January 2015, the Company amended and restated the 2011 Equity Incentive Plan (the “2011 Plan”). The Amendment and Restatement increased the aggregate number of shares of its common stock that may be issued pursuant to stock awards under the plan. In accordance with the rules of the TSX Venture Exchange regarding equity incentive plans, the number of shares that can be reserved for issuance under the 2011 Plan is equal to 20% of the Company’s common stock outstanding at the completion of the offering. 6,453,069 Preferred Stock Upon the completion of the IPO on January 6, 2015 each outstanding share of Series B Preferred Stock was automatically converted into one share of common stock. The Company converted 5,400,000 5,400,000 Stock Options The Company has one incentive stock plan, the 2011 Plan, and has granted stock options to employees, non-employee directors and consultants from the 2011 Plan. Options granted under the Plan may be Incentive Stock Options or Non-statutory Stock Options, as determined by the Administrator at the time of grant. At June 30, 2015, 3,843,258 During the year ended December 31, 2014, the Company granted an option to purchase 127,532 0.26 0.87 46,119 The Company recorded $ 70,691 222,136 216,205 222,498 Weighted Average Stock Options Exercise Price Fair Value Contractual Aggregate Outstanding Exercisable Outstanding Exercisable Vested Life (Years) Intrinsic Value Balance – December 31, 2014 2,609,811 459,437 $ 0.38 $ 0.17 $ 0.17 9.57 $ - Granted 786,696 786,696 1.00 1.00 0.38 1.27 - Exercised (55,548) (55,548) - - - - - Cancelled - - - - - - - Balance – June 30, 2015 3,340,959 1,472,471 $ 0.62 $ 0.31 $ 0.31 7.30 $ 1,347,163 Weighted Weighted Weighted Exercise Number Average Remaining Average Number Average Price Outstanding Contractual Term Exercise Price Exercisable Exercise Price $ 0.05 72,876 6.76 $ 0.05 62,248 $ 0.05 $ 0.26 1,061,248 8.78 $ 0.26 606,158 $ 0.26 $ 0.73 1,475,687 9.38 $ 0.73 72,917 $ 0.73 $ 1.00 731,148 1.02 $ 1.00 731,148 $ 1.00 Totals 3,340,959 1,472,471 Agent’s Compensation Options In connection with the closing of its IPO in January 2015 the Company issued 786,696 1.00 The Compensation Options expire on July 6, 2016. Each whole warrant issuable upon exercise of Compensation Options is exercisable to acquire one share of common stock at an exercise price of $2.00 per share at any time up to January 6, 2017, subject to the Company’s right to accelerate the expiration time of the warrants if at any time the volume-weighted average trading price of its common stock is equal to or exceeds $3.00 per share for twenty (20) consecutive trading days. During the six months ended June 30, 2015, a total of 55,548 55,548 Warrants During the six months ended June 30, 2015, the Company issued 7,002,774 The warrants are exercisable through January 6, 2017 at a price of $2.00 per share. The warrants are subject to the Company’s right to accelerate the expiration time of the warrants if at any time the volume-weighted average trading price of its common stock is equal to or exceeds $3.00 per share for twenty (20) consecutive trading days. As of June 30, 2015, the Company has warrants outstanding and exercisable to purchase 7,936,391 shares of common stock. Such warrants have a weighted average exercise price of $ 1.80 2.3 721,145

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 7 - Related Party Transactions Two of the Company’s Directors each provide it consulting services pursuant to agreements that provide for annual compensation of $ 42,000 10,500 8,083 21,000 11,083

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 8 - Subsequent Events Management has evaluated subsequent events to determine if events or transactions occurring through the date on which the financial statements were issued require adjustment or disclosure in the Company’s financial statements. During July 2015, the Company issued 318,124 1.00

Summary of Significant Accoun14

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at dates of the financial statements and the reported amounts of revenue and expenses during the periods. Actual results could differ from these estimates. The Company’s significant estimates and assumptions include the fair value of the Company’s stock, stock-based compensation, debt discount and the valuation allowance relating to the Company’s deferred tax assets.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk The Company maintains deposits in a financial institution which is insured by the Federal Deposit Insurance Corporation (“FDIC”). At various times, the Company has deposits in this financial institution in excess of the amount insured by the FDIC.
Investment, Policy [Policy Text Block]	Investments Investments consist of U.S Treasury Bills and Certificates of Deposit. The Company determines the appropriate balance sheet classification of its investments at the time of purchase and evaluates the classification at each balance sheet date. The Company had $ 4,745,714
Deferred Charges, Policy [Policy Text Block]	Deferred Offering Costs The Company classifies amounts related to the IPO not closed as of the balance sheet date as Deferred Offering Costs. During the six months ended June 30, 2015, the Company reclassified Deferred Offering Costs in the amount of $ 749,386 During the six months ended June 30, 2015, the Company incurred $ 35,811
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company utilizes three levels of inputs that may be used to measure fair value: Level 1 - quoted prices in active markets for identical assets or liabilities Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions) The carrying amounts of cash, investments, accounts payable, accrued liabilities and debt approximate fair value due to the short-term nature of these instruments.
Common Stock Purchase Warrants [Policy Text Block]	Common Stock Purchase Warrants The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provides the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company's own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control), or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its common stock purchase warrants and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required. The Company’s free standing derivatives consist of warrants to purchase common stock that were issued in connection with its notes payable, warrants to purchase common stock that were issued in connection with the Company’s IPO and concurrent private placement and compensation options issued to the agents in the IPO exercisable for shares of common stock and common stock purchase warrants. The Company evaluated these securities to assess their proper classification using the applicable criteria enumerated under U.S. GAAP and determined that they meet the criteria for equity classification in the condensed balance sheet as of June 30, 2015 and December 31, 2014.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share-Based Payment The Company accounts for share-based payments using the fair value method. For employees and directors, the fair value of the award is measured, as discussed below, on the grant date. For non-employees, fair value is generally valued based on the fair value of the services provided or the fair value of the equity instruments on the measurement date, whichever is more readily determinable and re-measured on each financial reporting dates until the service is complete. The Company has granted stock options at exercise prices no less than the fair market value as determined by the board of directors, with input from management. The weighted-average fair value of options and warrants has been estimated on the date of grant using the Black-Scholes pricing model. The fair value of each instrument is estimated on the date of grant utilizing certain assumptions for a risk free interest rate, volatility and expected remaining lives of the awards. Since the Company has a limited history of being publicly traded, the fair value of stock-based payment awards issued was estimated using a volatility derived from an index of comparable entities. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company’s stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company’s forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the number of vested options as a percentage of total options outstanding. If the Company’s actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period. For The Three And Six Months Ended June 30, 2015 2014 Expected life 4 years 6 years Risk free interest rate 1.32% 2.67% Expected volatility 80% 80% Expected dividend yield 0% 0% As of June 30, 2015, total unrecognized stock option compensation expense is $ 771,236
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share of Common Stock Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. June 30, June 30,* 2015 2014 Options 3,340,959 1,225,219 Warrants 7,936,391 833,617 Preferred Stock Series B - 2,600,000 Totals 11,277,350 4,658,836 * June 30, 2014 does not include shares and common stock purchase warants issuable under Put Agreements contingent upon the completion of the IPO.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Recent accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s financial statements upon adoption.

Summary of Significant Accoun15

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The weighted-average Black-Scholes assumptions are as follows: For The Three And Six Months Ended June 30, 2015 2014 Expected life 4 years 6 years Risk free interest rate 1.32% 2.67% Expected volatility 80% 80% Expected dividend yield 0% 0%
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	June 30, June 30,* 2015 2014 Options 3,340,959 1,225,219 Warrants 7,936,391 833,617 Preferred Stock Series B - 2,600,000 Totals 11,277,350 4,658,836 * June 30, 2014 does not include shares and common stock purchase warants issuable under Put Agreements contingent upon the completion of the IPO.

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses consist of: As of As of June 30, 2015 December 31, 2014 Lab services $ 44,329 $ 64,768 Professional fees 36,820 173,829 Consultant fees 4,000 52,000 Interest 14,315 10,804 Expense reimbursement 1,831 4,000 Total accrued expenses $ 101,295 $ 305,401

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table represents stock option activity for the six months ended June 30, 2015: Weighted Average Stock Options Exercise Price Fair Value Contractual Aggregate Outstanding Exercisable Outstanding Exercisable Vested Life (Years) Intrinsic Value Balance – December 31, 2014 2,609,811 459,437 $ 0.38 $ 0.17 $ 0.17 9.57 $ - Granted 786,696 786,696 1.00 1.00 0.38 1.27 - Exercised (55,548) (55,548) - - - - - Cancelled - - - - - - - Balance – June 30, 2015 3,340,959 1,472,471 $ 0.62 $ 0.31 $ 0.31 7.30 $ 1,347,163
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table summarizes information on stock options outstanding and exercisable as of June 30, 2015: Weighted Weighted Weighted Exercise Number Average Remaining Average Number Average Price Outstanding Contractual Term Exercise Price Exercisable Exercise Price $ 0.05 72,876 6.76 $ 0.05 62,248 $ 0.05 $ 0.26 1,061,248 8.78 $ 0.26 606,158 $ 0.26 $ 0.73 1,475,687 9.38 $ 0.73 72,917 $ 0.73 $ 1.00 731,148 1.02 $ 1.00 731,148 $ 1.00 Totals 3,340,959 1,472,471

Management's Liquidity Plans (D

Management's Liquidity Plans (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 31, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Subsidiary, Sale of Stock [Line Items]
Working Capital		$ 11,838,609		$ 11,838,609
Stockholders' Equity Attributable to Parent		11,860,849		11,860,849		$ 1,069,604
Net Loss		$ 867,530	$ 662,567	$ 1,648,795	$ 916,978
Proceeds from Issuance of Common Stock	$ 13,950,000
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	11,250,000
Share Price	$ 1
Stock Issued During Period, Value, New Issues	$ 11,250,000
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	2,700,000
Stock Issued During Period, Value, New Issues	$ 2,700,000

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Details)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Weighted Average [Line Items]
Expected life	4 years	6 years
Risk free interest rate	1.32%	2.67%
Expected volatility	80.00%	80.00%
Expected dividend yield	0.00%	0.00%

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Details 1) - shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	[1]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	11,277,350	4,658,836
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	7,936,391	833,617
Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	2,600,000
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,340,959	1,225,219
[1]	June 30, 2014 does not include shares and common stock purchase warants issuable under Put Agreements contingent upon the completion of the IPO.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Investments	$ 4,745,714	$ 0
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	749,386
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 771,236
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term	4 years
Additional Offering Related Costs	$ 35,811

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Accrued Expenses [Line Items]
Lab services	$ 44,329	$ 64,768
Professional fees	36,820	173,829
Consultant fees	4,000	52,000
Interest	14,315	10,804
Expense reimbursement	1,831	4,000
Total accrued expenses	$ 101,295	$ 305,401

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Operating Leased Assets [Line Items]
Operating Leases, Rent Expense, Net	$ 26,727	$ 5,400	$ 45,742	$ 10,800

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Equity Option [Member] - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Stock Options Outstanding
Balance - December 31, 2014	2,609,811
Granted	786,696
Exercised	(55,548)
Cancelled	0
Balance - June 30, 2015	3,340,959	2,609,811
Stock Options Exercisable
Balance - December 31, 2014	459,437
Granted	786,696
Exercised	(55,548)
Cancelled	0
Balance - June 30, 2015	1,472,471	459,437
Weighted Average Exercise Price Outstanding
Balance - December 31, 2014	$ 0.38
Granted	1
Exercised	0
Cancelled	0
Balance - June 30, 2015	0.62	$ 0.38
Weighted Average Exercise Price Exercisable
Balance - December 31, 2014	0.17
Granted	1
Exercised	0
Cancelled	0
Balance - June 30, 2015	0.31	0.17
Weighted Average Fair Value Vested
Balance - December 31, 2014	0.17
Granted	0.38
Exercised	0
Cancelled	0
Balance - June 30, 2015	$ 0.31	$ 0.17
Weighted Average Contractual Life (Years)
Granted	1 year 3 months 7 days
Exercised
Cancelled
Balance	7 years 3 months 18 days	9 years 6 months 25 days
Aggregate Intrinsic Value
Balance - December 31, 2014	$ 0
Granted	0
Exercised	0
Cancelled	0
Balance - June 30, 2015	$ 1,347,163	$ 0

Stockholders' Equity (Details 1

Stockholders' Equity (Details 1) - Jun. 30, 2015 - $ / shares	Total
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Options Number Outstanding	3,340,959
Stock Options Number Exercisable	1,472,471
Exercise Price 0.05 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Options Number Outstanding	72,876
Stock Options Outstanding Weighted Average Remaining Contractual Term	6 years 9 months 4 days
Stock Options Outstanding Weighted Average Exercise Price	$ 0.05
Stock Options Number Exercisable	62,248
Stock Options Exercisable Weighted Average Exercise Price	$ 0.05
Exercise Price 0.26 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Options Number Outstanding	1,061,248
Stock Options Outstanding Weighted Average Remaining Contractual Term	8 years 9 months 11 days
Stock Options Outstanding Weighted Average Exercise Price	$ 0.26
Stock Options Number Exercisable	606,158
Stock Options Exercisable Weighted Average Exercise Price	$ 0.26
Exercise Price 0.73 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Options Number Outstanding	1,475,687
Stock Options Outstanding Weighted Average Remaining Contractual Term	9 years 4 months 17 days
Stock Options Outstanding Weighted Average Exercise Price	$ 0.73
Stock Options Number Exercisable	72,917
Stock Options Exercisable Weighted Average Exercise Price	$ 0.73
Exercise Price 1 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Options Number Outstanding	731,148
Stock Options Outstanding Weighted Average Remaining Contractual Term	1 year 7 days
Stock Options Outstanding Weighted Average Exercise Price	$ 1
Stock Options Number Exercisable	731,148
Stock Options Exercisable Weighted Average Exercise Price	$ 1

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	Jan. 06, 2015	Jan. 31, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Common Stock, Shares Authorized			75,000,000		75,000,000		75,000,000
Common Stock, Par or Stated Value Per Share			$ 0.001		$ 0.001		$ 0.001
Preferred Stock, Shares Authorized			5,000,000		5,000,000		5,000,000
Preferred Stock, Par or Stated Value Per Share			$ 0.001		$ 0.001		$ 0.001
Equity Incentive Plan Description					In accordance with the rules of the TSX Venture Exchange regarding equity incentive plans, the number of shares that can be reserved for issuance under the 2011 Plan is equal to 20% of the Companys common stock outstanding at the completion of the offering.
Common Stock, Capital Shares Reserved for Future Issuance			3,843,258		3,843,258
Share-based Compensation			$ 70,691	$ 222,136	$ 216,205	$ 222,498
Proceeds from Stock Options Exercised					$ 55,548	$ 0
Two Agent [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period					55,548
Proceeds from Stock Options Exercised					$ 55,548
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							127,532
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price							$ 0.26
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value							$ 0.87
Allocated Share-based Compensation Expense					$ 46,119
Compensation Options [Member]
Warrants To Purchase Common Stock			7,002,774		7,002,774
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		786,696
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 1
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding		The Compensation Options expire on July 6, 2016. Each whole warrant issuable upon exercise of Compensation Options is exercisable to acquire one share of common stock at an exercise price of $2.00 per share at any time up to January 6, 2017, subject to the Companys right to accelerate the expiration time of the warrants if at any time the volume-weighted average trading price of its common stock is equal to or exceeds $3.00 per share for twenty (20) consecutive trading days.			The warrants are exercisable through January 6, 2017 at a price of $2.00 per share. The warrants are subject to the Companys right to accelerate the expiration time of the warrants if at any time the volume-weighted average trading price of its common stock is equal to or exceeds $3.00 per share for twenty (20) consecutive trading days.
Common Stock [Member]
Conversion of Stock, Shares Converted	5,400,000
Warrant [Member]
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Exercise Price			$ 1.80		$ 1.80
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms					2 years 3 months 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding			$ 721,145		$ 721,145
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Outstanding and Exercisable			7,936,391		7,936,391
Amendment [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		80,000,000
Common Stock, Shares Authorized		75,000,000
Common Stock, Par or Stated Value Per Share		$ 0.001
Preferred Stock, Shares Authorized		5,000,000
Preferred Stock, Par or Stated Value Per Share		$ 0.001
IPO and Private Placement [Member]
Warrants To Purchase Common Stock		6,975,000
Proceeds from Issuance or Sale of Equity		$ 13,950,000
Stock Issued During Period, Shares, New Issues		13,950,000
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding		Each whole warrant is exercisable to acquire one share of CohBar's common stock at a price of $2.00 per share at any time up to January 6, 2017, subject to CohBar's right to accelerate the expiration time of the warrants if at any time the volume-weighted average trading price of its common stock is equal to or exceeds $3.00 per share for twenty (20) consecutive trading days.
Proceeds from Debt, Net of Issuance Costs		$ 12,953,484
IPO [Member]
Class Of Warrant Or Rights Issued During Period		11,250,000
Share Price		$ 1
Stock Issued During Period, Shares, New Issues		11,250,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		786,696
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 1
Common Stock, Capital Shares Reserved for Future Issuance		6,453,069
Private Placement [Member]
Proceeds from Issuance of Warrants		$ 2,700,000
Stock Issued During Period, Shares, New Issues		2,700,000
Series B Preferred Stock [Member]
Conversion of Stock, Shares Converted	5,400,000

Related Party Transactions (Det

Related Party Transactions (Details Textual) - Two Directors [Member] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense			$ 42,000
Consulting Fees	$ 10,500	$ 8,083	$ 21,000	$ 11,083

Subsequent Events (Details Text

Subsequent Events (Details Textual) - 1 months ended Jul. 31, 2015 - Consultant [Member] - Subsequent Event [Member] - Employee Stock Option [Member] - $ / shares	Total
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	318,124
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 1